Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.58 |
| ▸ | HTR7 | P34969 | 4/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071354 | 0.87 | HPGDS (0.73) | HPGDSHTR7DRD2HTR1AHTR6 | |
| SCHEMBL1365939 | 0.85 | HPGDS (0.61) | HPGDSHTR7DRD2DRD4CCR3 | |
| SCHEMBL1366085 | 0.84 | CCR3 (0.61) | HPGDSDRD2DRD4CCR3 | |
| SCHEMBL347916 | 0.84 | HPGDS (0.80) | HPGDSHTR7DRD2DRD4CCR3 | |
| SCHEMBL2071480 | 0.83 | HPGDS (0.76) | HPGDSHTR7DRD2HTR1AHTR6 | |
| SCHEMBL1364516 | 0.83 | HPGDS (0.59) | HPGDSHTR7DRD2DRD4CCR3 | |
| SCHEMBL1364288 | 0.83 | CCR3 (0.63) | HPGDSDRD2DRD4CCR3SSTR5 | |
| SCHEMBL1368210 | 0.83 | HPGDS (0.55) | HPGDSHTR7DRD2DRD4CCR3 | |
| SCHEMBL348209 | 0.83 | HPGDS (0.56) | HPGDSHTR7DRD2DRD4CCR3 | |
| SCHEMBL1364852 | 0.82 | HPGDS (0.58) | HPGDSHTR7DRD2DRD4CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067589-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | BLAKE TANISHA D | 2009-11-12 | — | — | US | disclosed |
| US-7582643-B2 | Heterocyclic compounds useful in treating diseases and conditions | PFIZER INC (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | BLAKE TANISHA D | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281125-A1 | Heterocyclic Compounds Useful in Treating Diseases and Conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885HTR7 658/4885DRD2 4108/4885 |
| US-20080207651-A1 | Heterocyclic compounds useful in treating diseases and conditions | CYP11B2, CYP11B1, LTC4S | HPGDS 99/4885HTR7 658/4885DRD2 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.